Beryl Drugs FY26 net profit falls to ₹42.48 lakh

Beryl Drugs Limited reported a net profit of ₹42.48 lakh for the financial year ended March 31, 2026, a decrease from ₹56.75 lakh in the previous year. Revenue from operations for the year stood at ₹1931.02 lakh, compared to ₹2255.48 lakh in FY25. The decline in revenue was attributed to a temporary suspension of production operations in the Blow Fill Seal (BFS) Section following an order from the Office of the Controller, Food and Drugs Administration, Madhya Pradesh, which was later revoked in November 2025.

The board of directors, chaired by Sudhir Sethi, approved the audited financial results for the quarter and year ended March 31, 2026. The Statutory Auditor, M/s Subhash Chand Jain Anurag & Associates Chartered Accountants, issued an unmodified opinion on the results. The auditor highlighted an unrecorded potential liability regarding professional tax and the adoption of Ind AS 116 – Leases, which resulted in the recognition of a Right-of-Use asset of ₹27.75 lakh and a Lease Liability of ₹4.95 lakh.

Financial Performance

The company's total expenses for FY26 amounted to ₹1931.02 lakh, lower than the ₹2255.48 lakh recorded in the previous year. Profit before tax for the year was ₹58.80 lakh, compared to ₹85.43 lakh in FY25. For the quarter ended March 31, 2026, the company reported a net profit of ₹56.25 lakh and revenue from operations of ₹546.74 lakh.

Key Financial Metrics (FY26)

Metric	Amount (₹ in lakh)	Previous Year (₹ in lakh)
Revenue from Operations	1931.02	2255.48
Total Expenses	1931.02	2255.48
Profit Before Tax	58.80	85.43
Net Profit	42.48	56.75
Earnings Per Share (Basic)	0.84	1.12

The company's cash and cash equivalents as of March 31, 2026, were ₹27.35 lakh, down from ₹81.44 lakh in the previous year. The balance sheet total assets stood at ₹1496.33 lakh as of March 31, 2026. The filing was submitted to the Bombay Stock Exchange Limited in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.14%	+7.56%	-2.06%	-4.64%	+10.68%	+129.08%

Beryl Drugs Limited has scheduled a board meeting for May 28, 2026, to transact significant business regarding the company's financial performance for the fiscal year ending March 31, 2026. The meeting will be held at the company's registered office in Indore at 02:00 P.M.

The primary agenda item involves the consideration and approval of the audited financial statements, including the balance sheet as of March 31, 2026. Additionally, the board will review the statement of profit and loss, cash flow statement, and accompanying notes for the financial year.

Agenda for the Meeting

The board is set to deliberate on several key resolutions during the session:

To consider and approve the Audited Financial Statement including Balance Sheet, as at 31st March, 2026, Statement of Profit and Loss, Cash Flow and Notes thereon for the year ended 31st March, 2026.
To take on record the Auditors report of the Statutory Auditor for the Financial Results of the Company for the year ended on 31st March, 2026.
To consider and approve the related party transaction.
To consider any other resolutions with the permission of the chair.

The meeting notice was issued by Sanjay Sethi, Managing Director of beryl drugs . The company has requested the Bombay Stock Exchange to take the intimation on record.